Skip to main content

Table 1 Clinical characteristics of the patients at baseline and at year 1 a

From: Lack of change in urate deposition by dual-energy computed tomography among clinically stable patients with long-standing tophaceous gout: a prospective longitudinal study

Characteristics

Baseline

Year 1

Male sex, n (%)

67 (92%)

Age, years

58 (49 to 65)

Pacific ethnicity, n (%)

25 (34%)

Māori ethnicity, n (%)

18 (25%)

European and other ethnicities, n (%)

30 (41%)

Gout disease duration, years

23 (16 to 28)

Flare frequency (in the preceding three months)

0 (0 to 2)

0 (0 to 2)

Allopurinol use, n (%)

62 (85%)

62 (85%)

Allopurinol dose (n = 62), mg/day

300 (200 to 300)

300 (200 to 300)

Colchicine use, n (%)

33 (45%)

32 (44%)

Nonsteroidal anti-inflammatory drug use, n (%)

46 (63%)

44 (60%)

Prednisone use, n (%)

11 (15%)

12 (16%)

Health assessment questionnaire II score

0.2 (0 to 0.55)

0.15 (0 to 0.58)

Swollen joint count

0 (0 to 0)

0 (0 to 0)

Tender joint count

0 (0 to 1)

0 (0 to 1)

Number of subcutaneous tophi

3 (2 to 9)

3.5 (2 to 8)

Serum creatinine, μmol/L

99 (84 to 112.5)

96 (81 to 112)

C-reactive protein, mg/L

2.4 (1 to 5)

2.1 (1 to 6)

Serum urate, mmol/L

0.36 (0.18 to 0.46)

0.37 (0.32 to 0.46)

Serum urate <0.36 mmol/L, n (%)

34 (47%)

29 (40%)

Serum urate <0.36 mmol/L at both time points, n (%)

21 (29%)

  1. aUnless otherwise specified, data are presented as medians (IQRs).